Results 201 to 210 of about 351,954 (346)

Extrachromosomal circular DNA of multiple myeloma. [PDF]

J Cancer
Li F, Long X, Tang S, Liu J, Fu Y.
europepmc   +1 more source

The BH3‐only protein NOXA is essential for apoptosis induction by BH3‐mimetics targeting BCL2 or BCL‐XL in DLBCL

British Journal of Haematology, EarlyView.
Summary BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B‐cell malignancies such as diffuse large B‐Cell lymphoma (DLBCL) is complicated by the more heterogeneous nature of the disease.
Nahide Yildirim, Marius Anders, Victoria M. Smith, Sandrine Jayne, Moritz Assmann, Rebekah Jukes‐Jones, Martin J. S. Dyer, Meike Vogler   +7 more
wiley   +1 more source

Immunoparesis in multiple myeloma: a current overview. [PDF]

Front Oncol
Wang H, Chen J.
europepmc   +1 more source

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma [PDF]

, 2014
Meletios Α. Dimopoulos, Xavier Leleu, Antonio Palumbo, Philippe Moreau, Michel Delforge, Michèle Cavo, Heinz Ludwig, Gareth J. Morgan, Faith E. Davies, Pieter Sonneveld, Stephen Schey, Sonja Zweegman, Mona Hansson, Katja Weisel, MV Mateos, T. Facon, Jesús F. San Miguel   +16 more
openalex   +1 more source

Artificial intelligence for risk assessment and outcome prediction in malignant haematology

British Journal of Haematology, EarlyView.
Machine learning models allow for dynamic and scalable risk stratification and outcome prediction. Different modalities of data such as electronic health records, patient genetics or laboratory results can be used as input. ML models autonomously select features weighing their prognostic value. Methods of model explainability in feature selection allow
Jan‐Niklas Eckardt, Wencke Walter, Jan Moritz Middeke, Torsten Haferlach   +3 more
wiley   +1 more source

National multiple myeloma cohort: Gaps and opportunities for research in Brazil. [PDF]

Hematol Transfus Cell Ther
Moreira do Amaral D.
europepmc   +1 more source

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

British Journal of Haematology, EarlyView.
Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate‐day dosing was less effective.
M. R. Seefat, D. G. J. Cucchi, L. van Boven, N. Durdu‐Rayman, K. Groen, M.‐D. Levin, K. de Heer, B. de Valk, R. Wester, E. van der Spek, R. Rentenaar, C. L. B. M. Korst, M. Quik, C. A. O'Neill, P. Tzortzi, F. Smits, R. Mathot, M. R. Heerma van Voss, N. W. C. J. van de Donk, T. Mutis, I. H. Bartelink, S. Zweegman   +21 more
wiley   +1 more source

The impact of STAiR18 on multiple myeloma survival rates. [PDF]

J Transl Med
Wu Y, Wang H, Luo J, Lin J, Wu Y, Zheng S, Gao Y, Chen J, Che F, Shi J, Zhong L.   +10 more
europepmc   +1 more source

Figure S7 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy [PDF]

Mingming Zhang, Linghui Zhou, Houli Zhao, Yanlei Zhang, Guoqing Wei, Ruimin Hong, Wenjun Wu, Huijun Xu, Linqin Wang, Fang Ni, Jiazhen Cui, Shuixiu Peng, Chih-Hua Huang, Alex H. Chang, Yongxian Hu, He Huang   +15 more
openalex   +1 more source

Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023. [PDF]

Front Oncol
Jiang Y, Liang G, Cao Y.
europepmc   +1 more source